menu

Use of Omega-3 Fatty Acids for ASCVD Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?

close
0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Drs. Cheeley and Saseen will discuss the biological effects of OM-3s and their mechanisms of action and review all recent major clinical trials. Faculty will share practical information for pharmacists on the use of icosapent ethyl vs. generic OM-3s and dietary supplements for ASCVD management.

    Upon completion of this activity you will be directed to the activity’s sponsor, Postgraduate Healthcare Education, LLC (PHE) to claim your ACPE credits.  Once there you will click, ‘Take Exam’ to claim your credits.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Mary Katherine Cheeley, PharmD, CLS, FNLA
    Clinical Pharmacist Specialist: Primary Care
    Grady Health System
    Atlanta, GA
    No relationship to report. 

    Joseph Saseen, PharmD, BCPS, BCACP, CLS  
    Professor and Associate Dean for Clinical Affairs
    University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy
    Aurora, CO
    No relationship to report.

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Sue Grossman has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • The clinical reviewer, Catherine Sheffield, PharmD, has no actual or potential conflicts of interest in relation to this educational activity.
    • Susanne Batesko, RN, BSN, Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss biologic effects of OM-3s and their mechanisms of action
    • Relate the recent major clinical trials on OM-3s and their clinical implications
    • Review strategies to have greater competence on use of icosapent ethyl, generic OM-3s, and dietary supplements for ASCVD management
  • Target Audience

    This activity is designed to meet the educational needs of Pharmacists.

  • Accreditation and Credit Designation Statements

    This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE).

    ReachMD Healthcare ImagePHARMACY
    Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    UAN: 0430-0000-21-081-H01-P
    Release Date: July 31, 2021
    Expiration Date: July 31, 2022
    Credits: 0.25 hour (0.025 CEUs)
    Type of Activity: Knowledge
    Media: Internet
    Fee Information: There is no fee for this educational activity.
    Estimated time to complete activity: 15 minutes.

    How to Earn Credit

    Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity in its entirety; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded.  If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC, Medtelligence, and PIM. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Drs. Cheeley and Saseen will discuss the biological effects of OM-3s and their mechanisms of action and review all recent major clinical trials. Faculty will share practical information for pharmacists on the use of icosapent ethyl vs. generic OM-3s and dietary supplements for ASCVD management.

    Upon completion of this activity you will be directed to the activity’s sponsor, Postgraduate Healthcare Education, LLC (PHE) to claim your ACPE credits.  Once there you will click, ‘Take Exam’ to claim your credits.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Mary Katherine Cheeley, PharmD, CLS, FNLA
    Clinical Pharmacist Specialist: Primary Care
    Grady Health System
    Atlanta, GA
    No relationship to report. 

    Joseph Saseen, PharmD, BCPS, BCACP, CLS  
    Professor and Associate Dean for Clinical Affairs
    University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy
    Aurora, CO
    No relationship to report.

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Sue Grossman has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • The clinical reviewer, Catherine Sheffield, PharmD, has no actual or potential conflicts of interest in relation to this educational activity.
    • Susanne Batesko, RN, BSN, Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss biologic effects of OM-3s and their mechanisms of action
    • Relate the recent major clinical trials on OM-3s and their clinical implications
    • Review strategies to have greater competence on use of icosapent ethyl, generic OM-3s, and dietary supplements for ASCVD management
  • Target Audience

    This activity is designed to meet the educational needs of Pharmacists.

  • Accreditation and Credit Designation Statements

    This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE).

    ReachMD Healthcare ImagePHARMACY
    Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    UAN: 0430-0000-21-081-H01-P
    Release Date: July 31, 2021
    Expiration Date: July 31, 2022
    Credits: 0.25 hour (0.025 CEUs)
    Type of Activity: Knowledge
    Media: Internet
    Fee Information: There is no fee for this educational activity.
    Estimated time to complete activity: 15 minutes.

    How to Earn Credit

    Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity in its entirety; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded.  If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC, Medtelligence, and PIM. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 9/18/21